13th Edition of International Conference on Neurology and Brain Disorders
October 19-21, 2026
Neurodevelopmental Disorders
Neurodevelopmental disorders refer to a diverse group of conditions that manifest during childhood and affect the growth and development of the nervous system. These disorders can result in impairments in areas such as communication, learning, social interaction, and motor skills. Conditions such as cerebral palsy, dyslexia, and developmental coordination disorder are key examples of neurodevelopmental disorders that impact both academic and social functioning. Research into the underlying causes of these disorders is uncovering the roles of genetics, prenatal factors, and early environmental influences. Interventions focusing on improving cognitive, behavioral, and motor skills, alongside family support, can significantly improve outcomes. Advances in neuroscience and genomics are opening new possibilities for early detection and personalized treatment strategies that aim to address the specific needs of affected individuals.
Ken Ware
NeuroPhysics Therapy Institute and Research Centre, Australia
Yong Xiao Wang
Albany Medical College, United States
Joe Sam Robinson
Mercer University, United States
Daniel Curry
Texas Children’s Hospital, United States
Steven Benvenisti
Davis, Saperstein Salomon, PC, United States
Andrzej Stanislaw Cieplak
Independent researcher, United States
Younok Dumortier Shin
OnusBio, United StatesSubmit your abstract Today
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States